2023 World Conference on Lung Cancer (Posters)-EP12.03. Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib.

EP12.03. Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib. - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the prognostic value of TP53 commutations among Hispanic patients with advanced EGFR-positive non-small cell lung cancer (NSCLC) treated with first-line Osimertinib. The study included 72 patients who were treated with Osimertinib between January 2017 and January 2023. Molecular profiling was performed, and clinicopathological features and treatment outcomes were evaluated.<br /><br />The results showed that 32% of the patients had TP53 mutations. The patients with TP53 mutations were younger, predominantly female, and had adenocarcinomas. They also had a higher number of genomic alterations and a higher tumor mutational burden (TMB). In contrast, patients without TP53 mutations had different characteristics, such as a higher prevalence of the del19 mutation.<br /><br />The study found that TP53 mutations negatively impacted the overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) to Osimertinib. The ORR was lower in patients with TP53 mutations compared to those without, and the PFS and OS were shorter. TP53 mutations and high TMB were identified as factors that significantly affected OS in the multivariate analysis.<br /><br />The study concluded that the presence of TP53 commutations in Hispanic patients with EGFR-positive NSCLC negatively impacted the response to Osimertinib and overall prognosis. The biology of EGFR/TP53 tumors appeared to be more aggressive, particularly in the presence of the L858R variant. Further prospective studies are needed to better understand this population and explore additional treatment options for patients with EGFR/TP53 mutations and high TMB.

Asset Subtitle

Leonardo Rojas

Meta Tag

Speaker Leonardo Rojas

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

TP53 mutations

Hispanic patients

EGFR-positive NSCLC

Osimertinib

molecular profiling

clinicopathological features

tumor mutational burden

overall response rate

progression-free survival

overall survival